Dimerix Limited Dimerix Limited
  • About
    • Board / Management
    • Company Strategy
  • ACTION3 Phase 3 Study
    • ACTION3 for Patients
  • Technology
  • Pipeline
    • DMX-700 for Chronic Obstructive Pulmonary Disease (COPD)
    • DMX-200 for Focal Segmental Glomerulosclerosis (FSGS)
  • Partnering
  • Investor Centre
    • Announcements & Media Releases
    • Analyst Reports
    • Share Price & Graph
    • Investor Services
    • Corporate Governance
    • Board & Management
    • Corporate Factsheet
Contact Us
  • About
    • Board / Management
    • Company Strategy
  • ACTION3 Phase 3 Study
    • ACTION3 for Patients
  • Technology
  • Pipeline
    • DMX-700 for Chronic Obstructive Pulmonary Disease (COPD)
    • DMX-200 for Focal Segmental Glomerulosclerosis (FSGS)
  • Partnering
  • Investor Centre
    • Announcements & Media Releases
    • Analyst Reports
    • Share Price & Graph
    • Investor Services
    • Corporate Governance
    • Board & Management
    • Corporate Factsheet
Contact Us

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

  • Home
  • About
  • Technology
  • Pipeline
  • Investor Centre
  • Contact Us
  • ACTION3 for Patients

Dimerix HQ

425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com
© Copyright Dimerix 2024
True Agency
trueagency.com.au